HKHana Klamova

Hana Klamova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hana Klamova has a total of 145 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chronic myeloid leukaemia: have basophils gone the way of the Dodo bird?

    by Lucia Turcsanyi, Xiao-Shuai Zhang, Milos Kudelka, Kristyna Kubikova, Martin Radvansky, Sen Yang, Eva Kriegova, Jarmila Juranova, Jiri Mayer, Hana Klamova, et al.

  • Open Access

    Development of a prognostic scoring system for chronic myeloid leukemia in blast phase

    by Michael Lauseker, Tomasz Sacha, Hana Klamova, Julia Yakoleva, Elza Lomaia, Dragana Milojkovic, Christian Fabisch, Franck E. Nicolini, Ulla Olsson-Stromberg, Daniela Zackova, et al.

    Currently there is no established prognostic scoring system for patients with chronic myeloid leukemia (CML) in blast phase (BP). This study aimed to identify prognostic factors of CML-BP in a large cohort of prospectively and retrospectively collected patients and to develop a readily available prognostic scoring system at the onset of BP to enable future comparison between different trials and series. The analyses were based on 275 patients from thirteen countries, collected within the European LeukemiaNet Blast Phase Registry with a median observation time of 45 months and a median OS of 18.9 months. A Cox proportional hazards model for overall survival (OS) was employed, missing values were imputed. The study identified six independent prognostic factors: blast percentage, platelet count, age (all at onset of CML-BP), immunophenotype of BP, extramedullary disease, and previous history of CML. The low-risk group, encompassing 14% of patients, had a median OS of 97 months, the intermediate-risk group (59% of patients) of 22 months, and the high-risk group (27% of patients) of 9 months. Cross-validation demonstrated a good performance of the score, although external validation is strongly recommended. Despite the inherent limitations of registry data, the findings offer robust insights into prognostic factors for CML-BP.


  • Open Access

    Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia

    by Jitka Krizkova, Vaclava Polivkova, Adam Laznicka, Nikola Curik, Adela Benesova, Pavla Suchankova, Tomas Smazik, Veronika Vysinova, Dana Mikulenkova, Hana Klamova, et al.

    Adolescent and young adults (AYAs) with chronic myeloid leukemia in chronic phase (CML-CP) reportedly respond worse to tyrosine kinase inhibitors (TKIs) than adults, potentially due to additional genetic abnormalities, including mutations in cancer-related genes (CRGs). This real-life study compared mutation profiles and their impact on outcomes in 80 AYA, 97 adult, and 16 pediatric CML-CP patients, alongside 81 BCR::ABL1-positive acute lymphoblastic leukemia (Ph+ ALL) patients. CRG mutations were more frequent in AYAs (25.0%) than in adults (19.6%) or children (12.5%). AYAs with Ph+ ALL exhibited higher mutational frequencies (53.3%) compared to children (26.7%) and adults (38.9%). At diagnosis, mutations in ASXL1, DNMT3A, and TET2 dominated in CML-CP and RUNX1, IKZF1, and BCR::ABL1 in Ph+ ALL. ASXL1 mutations correlated with reduced progression-free survival (PFS) in AYAs and adults. Unlike adults, AYAs showed no increase in BCR::ABL1 kinase domain mutations during TKI therapy. Nilotinib improved PFS in AYAs with ASXL1 mutations, highlighting the efficacy of higher-generation TKIs. ASXL1 mutations also impaired erythropoiesis, warranting further validation. Despite a higher mutational burden, AYAs did not exhibit worse prognoses than adults. Lower mutation rates at follow-up suggest potential impact of nilotinib. Mutation profiling and optimized TKI use are crucial to mitigate progression risks in CRG-mutated patients.


  • Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia

    by Jiří Mayer, Petra Čičátková, Lenka Kováčová, Marie Jarošová, Michal Karas, Pavel Jindra, Hana Klamová, Kateřina Machová Poláková, Olga Černá, Eduard Cmunt, et al.

    The influence of t(v;22) sole, major route ACAs all (+8, n = 14; +Ph, n = 10; +19, n = 1), and -Y sole on progression-free survival. Survival curves are compared with those of patients with the standard t(9;22) translocation. Other ACAs or complex karyotypes did not influence survival.

  • Open Access

    Somatic Mutations and Outcomes in CML Adolescent and Young Adults Compared to Children, Adults, and BCR::ABL1-positive ALL Patients

    by Katerina Machova Polakova, Jitka Krizkova, Vaclava Polivkova, Adam Laznicka, Nikola Curik, Adela Benesova, Pavla Suchankova, Tomas Smazik, Veronika Vysinova, Dana Mikulenkova, et al.

    Adolescent and young adult (AYA) patients with chronic myeloid leukemia in chronic phase (CML-CP) reportedly fare worse on tyrosine kinase inhibitor (TKIs) than adults. This real-life study compared mutation profiles and outcomes in 80 AYA, 97 adult, and 16 pediatric CML-CP patients, alongside 81 BCR::ABL1-positive acute lymphoblastic leukemia (ALL) patients. Somatic mutations in cancer-related genes (CRGs) were more frequent in AYAs with CML-CP (25.0%) than in adults (19.6%) or children (12.5%). AYAs with Ph+ ALL also exhibited higher mutational frequencies (53.3%) compared to children (26.7%) and adults (38.9%). Mutation landscapes differed at diagnosis with ASXL1, DNMT3A, and TET2dominant in CML-CP and RUNX1, IKZF1, and BCR::ABL1predominated in Ph+ ALL. ASXL1 mutations correlated with reduced progression-free survival (PFS) in AYAs and adults, with adults showing increased BCR::ABL1 mutations during TKI therapy, a trend not observed in AYAs. Nilotinib improved PFS in AYAs with ASXL1 mutations, highlighting the efficacy of higher-generation TKIs. ASXL1 mutations also impaired erythropoiesis, warranting further validation. Despite a higher mutational burden, AYAs did not show worse prognoses than adults, with lower mutation rates at follow-up suggesting better adherence. Mutation profiling and optimized TKI use are crucial to mitigate progression risks in CRG-mutated patients.


  • Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

    by Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Franck E. Nicolini, Jiri Mayer, Daniela Zackova, Jeroen J. W. M. Janssen, Panayiotis Panayiotidis, et al.

    Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL results from the EURO-SKI trial. Patients who had been on tyrosine kinase inhibitors (TKIs) therapy for at least 3 years and achieved MR4 for at least 1 year were enrolled from 11 European countries, and the EORTC QLQ-C30 and the FACIT-Fatigue questionnaires were used to assess HRQoL and fatigue respectively. Patients were categorized into the following age groups: 18–39, 40–59, 60–69 and ≥70 years. Of 728 patients evaluated at baseline, 686 (94%) completed HRQoL assessments. The median age at TKI discontinuation was 60 years. Our findings indicate that HRQoL and symptom trajectories may vary depending on specific age groups, with younger patients benefiting the most. Improvements in patients aged 60 years or older were marginal across several HRQoL and symptom domains. At the time of considering TKI discontinuation, physicians could inform younger patients that they may expect valuable HRQoL benefits. Considering the marginal improvements observed in patients aged 60 years or above, it may be important to further investigate the value of TFR compared to a lowest effective dose approach in this older group of patients.


  • Open Access

    P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE

    by Lukas Semerad, Daniela Žáčková, Petra Belohlavkova, Jaroslava Voglova, Pavel Žák, Edgar Faber, Tomas Papajik, Ivana Skoumalova, Michal Karas, Pavel Jindra, et al.

  • Open Access

    Vascular adverse events in chronic myeloid leukaemia patients during tyrosine kinase inhibitor therapy in daily clinical practice – analysis from the INFINITY database

    by Petra Čičátková, Daniela Žáčková, Tomáš Horňák, Hana Klamová, Petra Bělohlávková, Lukáš Stejskal, Zlatuše Křístková, Jana Baranová, Anežka Kvetková, Lukáš Semerád, et al.

    The biggest source of information for doctors – proLékaře.cz

  • Open Access

    To the approximate size of the nuclear region occupied by nucleolar bodies during cell differentiation and maturation using the human leukemic granulocytic lineage as a convenient model

    by K. Smetana, H. Klamová, D. Mikulenková

    The present study was undertaken to estimate the approximate size of nuclear regions occupied by nucleolar bodies during the cell differentiation and maturation. The differentiation and maturation of human leukemic granulocytic cells in patients suffering from the chronic phase of the chronic granulocytic leukemia (CML) represented a convenient model for such study because of the large number of cells for the diameter measurements at the single cell level. Early and advanced differentiation or maturation stages of these cells are well defined and nucleolar bodies and nuclear outlines are easily seen by simple cytochemical methods for the visualization of RNA and silver stained proteins in smear preparations. During the cell differentiation and maturation, the estimated size of the nuclear region occupied by nucleolar bodies decreased in both untreated and treated patients with the anti-leukemic therapy. However, the size reduction of nucleolar bodies in differentiated and mature cells was larger than that of the nucleus. In addition, the results also indicated that the nuclear region occupied by nucleolar bodies was characteristic for each differentiation and maturation stage of the granulocytic cell lineage and was not substantially influenced by the anti-leukemic therapy of CML patients.


  • No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

    by Zdenek Racil, Filip Razga, Hana Klamova, Jaroslava Voglova, Petra Belohlavkova, Ludmila Malaskova, David Potesil, Jan Muzik, Daniela Zackova, Katerina Machova Polakova, et al.

    This multicentre study focused on monitoring imatinib mesylate (IMA) trough plasma (Ctrough) and intracellular (IMA Cintrac) concentrations in 228 chronic myelogenous leukaemia patients. The median of measured IMA Ctrough in our patient group was 905.8 ng ml (range: 27.7–4628.1 ng/ml). We found a correlation between IMA Ctrough and alpha 1‐acid glycoprotein plasma concentrations (rS = 0.42; p < 0.001). All other analysed parameters revealed only weak (gender, dose of IMA per kg) or not significant (age, albumin, creatinine plasma concentration or body mass index) impact on measured IMA Ctrough. The IMA Ctrough decreased during the first 6 months and significantly increased later during treatment. The IMA Ctrough at the first month of therapy did not differ between patients with and without an optimal response at the 12th (p = 0.724) and 18th month (p = 0.135) of therapy. There were no significant differences in medians of IMA Ctrough between both groups measured during the first year of treatment. The IMA Cintrac during the first month were not different between patients with and without an optimal response at the 6th (p = 0.273) and the 12th month (p = 0.193) of therapy. Our data obtained from real life clinical practice did not find a benefit of routine and regular IMA Ctrough nor IMA Cintrac therapeutic drug monitoring in chronic myelogenous leukaemia patients or for subsequent adjustments of the IMA dose based on these results. Moreover, actual alpha 1‐acid glycoprotein plasma concentration should be used for proper interpretation of IMA Ctrough results. Copyright © 2013 John Wiley & Sons, Ltd.